％0期刊文章％a nwaru，bright i.％aekström，magnus％a hasvold，pål％a wiklund，fredrik％a telg，gunilla％a Janson，Chanster％t过度使用短作用β₂哮喘的角度与加剧和死亡率的风险增加有关：全球塞巴娜计划的全国队列研究％d 2020％r 10.1183 / 13993003.01872-2019％j欧洲呼吸期轴颈％p 1901872％x背景过度使用短作用β2激动剂（SABA）可能表明哮喘差和健康状况不佳。基于当代人口的使用数据，风险因素和SABA（过度）对哮喘发恶臭和死亡率的影响是稀缺的，促使全球Sabina（SABA在哮喘中的SABA使用）计划ME.MEME.ME.MET.CHODS.ME.MEMEME.MET.CHODS包括≥2岁的患者12-45岁，≥22006 - 2014年阻塞性肺病药物收集。SABA过度使用定义为包含在纳入之后的一年基线期间> 2 SABA罐的集合。SABA使用分为3-5,6-10和11+罐/基线。Cox回归用于检查SABA使用和加重之间的关联（住院和/或OCS索赔）和死亡率。结果包括365个324哮喘患者（平均年龄27.6岁; 55％女性），平均随访时间为85.4个月。大约30％过剩的SABA，21％收集3-5个罐，7％6-10和2％11+罐·年1。越来越多的被收集的SABA罐与加剧风险增加有关：3-5（HR 1.26; [95％CI] 1.24-1.28）;6-10（1.44; 1.41-1.46）; and 11+ canisters (1.77; 1.72–1.83) compared to ≤2 canisters·year−1. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed): 3–5 (HR 1.26; 95% CI 1.14–1.39); 6–10 (1.67; 1.49–1.87); and 11+ canisters (2.35, 2.02–2.72) compared to ≤2 canisters·year−1.Conclusion One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr Nwaru reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Ekström reports personal fees from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Hasvold reports other from AstraZeneca, during the conduct of the study.Conflict of interest: Dr Telg reports personal fees from Employed by AZ, during the conduct of the study.Conflict of interest: Dr Christer Janson[AQ2] Conflict of interest: Dr Wicklund reports other from Statisticon/AstraZeneca, during the conduct of the study. %U //www.qdcxjkg.com/content/erj/early/2019/12/12/13993003.01872-2019.full.pdf